| Document |
Document Title |
|
WO/2023/134137A1 |
The present invention relates to the technical field of bioengineering. Provided in the present disclosure are a composition based on a supramolecular artificial receptor cell, and a preparation method therefor and the use thereof. Provi...
|
|
WO/2023/134713A1 |
The present invention belongs to the field of medicines, and relates to a fused azaheterocyclic compound, a pharmaceutical composition thereof and the use thereof in the preparation of a drug. Specifically, the present invention relates ...
|
|
WO/2023/137353A1 |
Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2023/137166A1 |
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a me...
|
|
WO/2023/134723A1 |
The present disclosure relates to a crystal form of a neurokinin antagonist prodrug compound. Specifically, the present disclosure relates to a novel crystal form of a compound represented by formula I and a preparation method. The novel...
|
|
WO/2023/137356A1 |
Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2023/135233A1 |
The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.
|
|
WO/2023/134629A1 |
The present disclosure relates to the field of drugs. Specifically, the present disclosure relates to a compound as represented by formula (I), or a stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug of the c...
|
|
WO/2023/135583A1 |
The present invention relates to vitamin nanoclusters (NCs), preferably vitamin D3nanoclusters, having a core-shell structure in which the solid core comprises vitamin, thereby defining a high-density or high-concentrated vitamin core. T...
|
|
WO/2023/135186A1 |
The present invention generally relates to the field of skin care. More particularly, the invention relates to a cosmetic or therapeutic skin care composition comprising live bacteria of at least one Cutibacterium acnes (C. acnes) strain...
|
|
WO/2023/136525A1 |
The purpose of the present invention is to provide a composition for prevention or treatment of particulate matter 2.5 (PM2.5)-induced inflammatory disease, comprising a powdered tea extract as an active ingredient, and more specifically...
|
|
WO/2023/134733A1 |
High penetration prodrugs (HPPs), pharmaceutical compositions and methods thereof, for treatment of signs, symptoms and/or complications of viral, bacterial, protozoal, and/or fungal infections are disclosed. The HPPs are capable of pene...
|
|
WO/2023/134765A1 |
The present invention relates to five-membered-ring-containing derivatives, a preparation method therefor, and the uses thereof. In particular, the present invention relates to compounds represented by a general formula, a preparation me...
|
|
WO/2023/136151A1 |
The present invention addresses the problem of providing a novel ASMT expression promoter and provides an ASMT expression promoter that contains, as an active ingredient, at least one substance selected from the group consisting of eucal...
|
|
WO/2023/134122A1 |
A cell membrane-coated nanodecoy (ND) capable of clearing proinflammatory factors and inhibiting T cell activation, and a preparation method therefor and the use thereof. The nanodecoy comprises: a nano core and a programmed death-ligand...
|
|
WO/2023/135532A1 |
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: (I) wherein R represents a 6-membered aryl or heteroaryl group or a 5-membered heteroaryl group, optionally substituted with at le...
|
|
WO/2023/132681A1 |
The present invention relates to a composition comprising 1-alkyl-5-arylidene-2-selenoxoimidazolidin-4-one and a derivative thereof for prevention, alleviation, or treatment of inflammatory diseases. Specifically, 1-alkyl-5-arylidene-2-s...
|
|
WO/2023/131578A1 |
The present invention relates to a combination of budesonide and 5-amino-2,3-dihydro-1,4- phthalazinedione or one of its pharmaceutically acceptable salts. This pharmaceutical combination shall be used in the treatment of chronic inflamm...
|
|
WO/2023/132399A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of inflammatory bowel disease, comprising a galacto-oligosaccharide as an active ingredient. The galacto-oligosaccharide composition of the pres...
|
|
WO/2023/133319A1 |
Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants (e.g., comprised in synthetic nanocarriers), wherein the immunosuppressant is at a reduced effe...
|
|
WO/2023/133386A1 |
The present disclosure relates to methods and compositions for oral delivery of nutrients and/or pharmaceuticals, particularly for tissue repair and regeneration of the body, and more particularly to methods and compositions for protecti...
|
|
WO/2023/130205A1 |
The present invention provides a stabilizing solution, a pharmaceutical composition stored or administered in a stabilizing solution form, and a pharmaceutical product of the stabilizing solution and preparation methods and applications ...
|
|
WO/2023/133089A1 |
Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions ther...
|
|
WO/2023/133460A1 |
Disclosed herein are methods of treating an allergic rhinitis, a nasal polyp, and/or a sinusitis in a subject, comprising intranasally administering to the subject a corticosteroid, an ester thereof, or a salt thereof by a nasal spray de...
|
|
WO/2023/131167A1 |
The present invention relates to a compound represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate thereof, a...
|
|
WO/2023/133445A1 |
Disclosed herein are compositions for and methods of treating, preventing, and/or mitigating pain, including both acute and chronic pain, post-surgical pain, cancer pain, injury pain, and pain associated with bone fracture. Disclosed her...
|
|
WO/2023/130160A1 |
The present invention relates to compositions comprising cannabinoids including cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), cannabidiphorol (CBDP), cannadibutol (CBDB), CBGA (cannabigerolic acid), CBN (cannabinol) a...
|
|
WO/2023/130185A1 |
A transformation vector for stably transforming a plastid is provided. The transformation vector comprises an expression cassette, comprising, as operably-linked components, a regulatory sequence operative in the plastid, a heterologous ...
|
|
WO/2023/130541A1 |
Provided in the present invention are a 2-pyrazole-3-benzimidazole derivative, a preparation method therefor and the use thereof, the 2-pyrazole-3-benzimidazole derivative having a structure represented by formula (I). Experimental resul...
|
|
WO/2023/133476A1 |
Disclosed herein is a method of treating Idiopathic Pulmonary Fibrosis (IPF). The method includes administering to a subject in need thereof the deuterium-enriched pirfenidone LYT-100 at a total daily dose from about 1650 mg to about 250...
|
|
WO/2023/130740A1 |
The present invention belongs to the technical field of biological medicines, and particularly relates to an isaridin cyclic lipopeptide derivative, and a preparation method therefor and the use thereof. Tests prove that the derivative s...
|
|
WO/2023/131142A1 |
A stable solution, a pharmaceutical composition with a storage or administration method as a stable solution, a pharmaceutical product of the stable solution, a preparation method therefor and the use thereof, and a kit. The stable solut...
|
|
WO/2023/130875A1 |
A botulinum toxin protein composition, comprising a botulinum toxin protein and a protein stabilizer. The protein stabilizer is selected from any one of amino acids and amino acid-like compounds, the amino acids being one or more of L-hi...
|
|
WO/2023/130161A1 |
The present invention relates to compositions comprising cannabinoids including cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), cannabidiphorol (CBDP), cannadibutol (CBDB), CBGA (cannabigerolic acid), CBN (cannabinol), ...
|
|
WO/2023/130354A1 |
Provided are two classes of substances for preventing and/or treating chronic and acute inflammatory disorders. The first study found a new class of TNF inhibitors (PRD, PRD-S, TAD, ZF7 peptide or a mixture thereof) that can be used to t...
|
|
WO/2023/124185A1 |
The invention provides an off-the-shelf human umbilical cord derived mesenchymal stem cell, a preparation method thereof, and an application. The preparation method comprises the following steps: culturing an isolated umbilical cord tiss...
|
|
WO/2023/128987A1 |
The present invention relates to a standardized extract of Allium sativum onions over allicin for use as an anti-inflammatory agent.
|
|
WO/2023/129946A1 |
Dosing methods and regimens and various dosage forms including formulations and kits for treating fever in children are provided. One dosing regimen or method for treating a febrile child comprises administering a dose to the child, the ...
|
|
WO/2023/124022A1 |
Provided is a thiophene[2,3-d]pyrimidine derivative represented by formula I or a pharmaceutically acceptable salt thereof, which can be used for preparing an RIPK2 inhibitor, and provides a new choice for preparing a drug for treating a...
|
|
WO/2023/126951A1 |
Disclosed herein are inhibitors of autophagy-related protein-protein interactions and their use for treating an autophagy-related disease or disorder, cancer, a cytokine release syndrome (CRS) or a cytokine storm in a subject.
|
|
WO/2023/125798A1 |
A traditional Chinese medicine composition for treating abnormal lung function and laryngitis caused by the influenza virus; the traditional Chinese medicine composition comprising as a primary formula of active ingredients seven medicin...
|
|
WO/2023/127961A1 |
According to the present invention, provided is a composition for inducing satiety or suppressing overeating.　This invention provides a GABA-containing composition for inducing transient satiety in a subject. This invention also provid...
|
|
WO/2023/125182A1 |
A compound as represented by general formula (I) or a stereoisomer, a deuterated form, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof; an intermediate thereof and a preparation method there...
|
|
WO/2023/128452A1 |
The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease, comprising extracts of Isatidis folium and Juglans mandshurica. In addition, the present invention relates to a food com...
|
|
WO/2023/125708A1 |
Disclosed in the present disclosure are a compound shown in formula (I), a racemate, stereoisomer, tautomer, isotopic label, solvate, pharmaceutically acceptable salt or prodrug thereof, a composition thereof, a preparation method theref...
|
|
WO/2023/126970A1 |
The present invention relates to new oral dosage forms of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof for veterinary use, such as for oral administration to animals. More specifically ...
|
|
WO/2023/129171A1 |
Pharmaceutical formulations comprising anti-inflammatory and/or pain-reducing agents that are insoluble or have low solubility in water are formulated with a solubility enhancer such as MSM to increase solubility. The enhanced solubility...
|
|
WO/2023/128556A1 |
The present invention provides a methotrexate conjugate in which sialyllactose capable of penetrating the blood-brain barrier is linked to methotrexate. Since the conjugate can penetrate the blood-brain barrier even when administered ora...
|
|
WO/2023/128990A1 |
The present invention relates to a standardized extract of Salvia triloba leaves over salvigenin for use as an anti-inflammatory agent.
|
|
WO/2023/128988A1 |
The present invention relates to a standardized extract of Malva sylvestris flowers over malvin for use as an anti-inflammatory agent.
|
